Clinical trial
A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002200 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection
NCT01590407 is registered in ClinicalTrials.gov with Alios Biopharma Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002200 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection
- Lead sponsor
- Alios Biopharma Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- February 28, 2013
- Enrollment
- 71 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.